Psychotropics and Youth, Part 2 – The Solutions
“Prescribed psychotropic medications are now high on the research agenda,” assert Lakhan and Hagger-Johnson. Their study advocates new approaches to research to address the rising concern over dramatic increases in psychotropic prescriptions for both children and young.
Our first post delineated the five erroneous myths often adhered to when prescribing youth’s psychotropic medication. Here are the three areas of recommended research to address this “alarming” problem.
1) Clarify child/adult differences for psychotropics. The future promises to see questionnaires and interviews tailored specifically to children and adolescents. Prominent will be the initiation of normative data for youth mental disorders. Studies will need to focus on specific age groups, disorders and treatments.
2) Attend to the growth of “cosmetic” use of psychotropics in children and adolescents. Researchers’ alarm over the marked increase in psychotropic prescriptions for youth has spilled over into the public arena. Recent media attention, in conjunction with changes in clinical practice standards and drug product labeling, has juggernauted psychotropic investigation to the forefront of the research agenda.
3) Address concerns about the diagnostic validity of mental illness in the current DSM classification system. Due to lack of psychotropic research on youth, the current DSM system is flawed, Lakhan and Hagger-Johnson noted. Ethical challenges such as reluctance to enroll children in psychotropic clinical trials and the lack of “well-designed”, placebo-controlled trials have traditionally been barriers to effective research. Increasingly, the idea of hands-on research with children is more palatable.
Lakhan and Haggar-Johnson remind us that “for the first time, we can begin to record and measure, rather than assume, the impact of prescribed psychotropics on children and adolescents.” The final verdict — children and adolescents need accurate, age-appropriate data that does not exist today.
Reference
Lakhan, S., & Hagger-Johnson, G. (2007). The impact of prescribed psychotropics on youth Clinical Practice and Epidemiology in Mental Health, 3 (1) DOI: 10.1186/1745-0179-3-21
Courtney Sherman, BA
Ms. Sherman is a graduate of the University of California, Los Angeles (History). She is a writer living in Los Angeles.8 Responses
[...] this grave problem. However, debate is continuing to grow about the over-reliance of psychotropics. In my next post, I will identify three areas of research that can provide answers to this alarming [...]
[...] 2010 ? 3 ? 10 ? ???? ???????? ???? Psychotropics and Youth, Part 2 – The Solutions | Brain Blogger “Prescribed psychotropic medications are now high on the research agenda,” assert [...]
[...] teachers involved in the study’s answer to this dilemma? They want more training in the area of child psychopharmacology and more collaboration with parents and physicians who prescribe the medication, which at present [...]
Leave a Reply
Popular Posts
- Mind Games - Science's Attempts at Thought Control
- The Science of Stuttering
- Intelligence - Are You Holding Back Your Brain?
- Risks of Personalized Medicine
- Is Grief a Mental Illness?
- The Brain's Buying Power
- The Cost of a Good Night's Sleep
- Risk Factors for Recurrence of Depression
- Salvia Divinorum - DEA Control over Magic in the Mint
- The Many Emerging Roles of Astrocytes
Future Posts
Latest Posts
- Thinking Fast Equals Risky Business
- A Gateway to Weight Loss?
- Intelligence – Do You Need it to be Successful?
- A Trip for Terminal Patients
- Memory Ain’t What It Used to Be – And That’s Good for Psychotherapy
- The Science of Stuttering
- Are Your Friends Making You Fat?
- Beer – The Smarter Drink
- Macroeconomics and Suicide
- From Nymphomania to Hypersexuality
Comments
- Dr. Linda Vu: I consider the plasticity in r
- karir: Hello there, just became aware
- akas: The rate of fashionable experi
- Ryan: Great post! I agree with the p
- : I have used heroin for 20 year
- Lino Baine: I am not aware that people wit
- Lulu Jones: Hmm....this is interesting. I
- Robert A. Yourell, MA: Hi Stephanie...OR they tried a
- Stephnie: Based on the facts in the arti
- Sammy: I was a test subject for one o
- Veronica Pamoukaghlian, MA: Thank you for your insightful
- Richard Kensinger, MSW: I agree w/ Howard Gardner's pe
Interesting piece. The third point really struck me. So the medical establishment believes its unethical to test these drugs on children — yet it’s all right to prescribe them willy-nilly without testing? Hello, people! — don’t we see a problem here?
Dear Bill,
I wrote on this issue for The Lancet Student last year:
You can read the full article here. I would like to know the public’s opinion on traditional clinical trials or using virtual models for testing medications on pediatric patients. Thank you.
Sincerely,
Shaheen
I agree Bill. They’d like to test children if society allowed it, but it’s not “in vogue” in the public sphere right now. You make a good point.
Thank you for your comments, Shaheen. Your article was quite interesting and your point astute. We should be well past the point where people recognize that children are not little adults, and be on a path to matching treatment to the specific ages and characteristics of the children involved. One-size-fits-all should never be a recipe for medical treatment of our children.
Psychotropics are clerly overprescribed for persons under the age of 10, even 5. Foster kids w/ “behavioral dyscontrol”, are 5 X more likely to be placed on “drug cocktails”, often 5 at a time!
I have very serious concerns about the schedule 2 controlled agents: the psychostimulants. The US prescribes 85% of the world market!
Likewise, the neuroleptics are very often inappropriately used in young kids. For example, for “irritability” in those w/ autism. They are only clinically indicated for those who are psychotic. In the clinical literature on autism, I see no concordance between autism & psychosis!
The neuroleptics at high doses & for long durations, show a range of serious side-effects, & adverse events, such as TD & NMS. Some of these conditions are irreversable & lethal.
Rich